Omada Health, Inc. OMDA R2K
Company Overview
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.
Why Investors Should Care
Revenue has grown at a 45.6% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $260.21M (+53.2% YoY); net profit $-12.78M.
- Trailing 12 Months Year-on-year growth — revenue +42.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 45.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 45.58% |
| 1 Year: | 42.00% |
Stock Price Performance
| 1 Year: | +33.56% |
| 6 Months: | +52.11% |
| 3 Months: | +93.40% |
| 1 Month: | +32.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross7d ago
- RSI (14)77.71 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 45.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 78 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OMDA Omada Health, Inc. R2K | 23.44 | -101.91 | $1.39B | 0.00% | -5.21% | -4.30% | 45.58% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 41.21M | 45.52M | 54.96M | 61.37M | 68.03M | 78.05M |
| Gross Profit | - | 24.83M | 28.56M | 31.90M | 40.31M | 45.07M | 48.69M |
| Operating Income | - | -10.04M | -8.52M | -8.40M | -4.34M | -2.51M | -4.78M |
| Net Income | -18.97M | -10.69M | -9.23M | -9.45M | -5.31M | -3.18M | -2.97M |
| Diluted EPS | - | -1.40 | -1.18 | -1.15 | -0.24 | -0.06 | -0.05 |
| R&D Expense | - | 8.99M | 8.85M | 8.81M | 10.02M | 10.30M | 12.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 122.78M | 169.80M | 260.21M |
| Gross Profit | 69.97M | 102.88M | 170.94M |
| Operating Income | -66.00M | -43.65M | -11.97M |
| Net Income | -67.51M | -47.14M | -12.78M |
| Diluted EPS | -9.52 | -6.11 | -0.35 |
| R&D Expense | 33.74M | 35.92M | 40.68M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | - | 150.89M | 305.41M |
| Total Equity | -293.17M | -350.11M | -384.40M | 229.68M |
| Cash & Equivalents | - | - | 76.39M | 222.04M |
| Long Term Debt | - | - | 29.77M | 0 |
| Total Liabilities | - | - | 86.26M | 75.73M |
| Current Liabilities | - | - | 53.95M | 75.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -49.74M | -34.18M | 18.25M |
| Investing Cash Flow | -2.92M | -3.86M | -5.83M |
| Financing Cash Flow | 179.00K | -1.21M | 133.22M |
| Capital Expenditure | -416.00K | -596.00K | -1.32M |
| Free Cash Flow | -50.15M | -34.77M | 16.93M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 57.0% | 60.6% | 65.7% |
| Operating Margin % | -53.8% | -25.7% | -4.6% |
| Net Margin % | -55.0% | -27.8% | -4.9% |
| ROE % | 19.3% | 12.3% | -5.6% |
| ROCE % | - | -45.0% | -5.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Divisadero Street Capital Management, LP | 9.90% | 5.89M | $134.77M |
| 2 | Revelation Capital Management, LLC | 8.76% | 5.21M | $119.21M |
| 3 | Cigna Investments Inc/New | 5.79% | 3.44M | $78.85M |
| 4 | FMR, LLC | 5.53% | 3.29M | $75.27M |
| 5 | NVP Associates, LLC | 4.26% | 2.53M | $57.93M |
| 6 | American Century Companies Inc | 4.13% | 2.46M | $56.22M |
| 7 | a16z Capital Management, L.L.C. | 3.88% | 2.31M | $52.81M |
| 8 | Blackrock Inc. | 3.20% | 1.90M | $43.60M |
| 9 | Vanguard Capital Management LLC | 3.04% | 1.81M | $41.41M |
| 10 | LOOMIS SAYLES & CO L P | 2.88% | 1.71M | $39.21M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OMDA
Omada Health, Inc. (OMDA) Stock Jumps 10.5%: Will It Continue to Soar? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPZkl5R3RINnFLajhnakpjcTVmNXZsRWhRWUppZ2dfRUFqZ1lBVXN4R3lKbHZfdkNSdUM2S2dRaDFZZTJjN3U2RVN3aGtMQmxseVQyZ1pUcHRiUVZ4YmEyRWpjVHFETk9LYU5sYUd5dFNKOVNyZktjSXJIeVg4T1ByQ2hCZUZraEU5T1VGdX…
OMDA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE85emx5aFR3NW9aRU1YSER4REIwaE9xaVlMR2V2YnVxeGxUMWRNYkhDTDBEUmFTRjJodUQ1SWlZRGVuMTI2N29MWENWOXRNNFZDd2xhMWJQSVQycWM5czA4VDlLWjc5bFhDb1NXM3UwZU1iWVBwd1ktcXRB?oc=5" target="_blank">OMD…
Omada Health, Inc. (OMDA) Is Up 7.18% in One Week: What You Should Know - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOYktMaUpHdVp6TURyYlpEb2puX3ZxMkxFemlkOWZXSVdtV0NlTnhRTVpnZjZ0VW1WWFpUR1hDcVFxVFYzVHFhRkxITjN6bm1qTXh0YV9MU1o1OC1NSGR3R2FFaHc4X1lkbXQxamw2cmhaTlZiSmJQYnFETlVPQUhpcXpCUHM4b2VraUg0c1…
OMADA HEALTH ($OMDA) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPNS1GNjlVaGpkTDVpT29naC1LTVh3RXBYTHNDX0NTYmZsOGh5a0FXQ0ZBRWxOR2hzZlNjSVdoeWtjLXd3dUJQcjllOWVJaGxkcVN3cDdrdHNJcWUzWlNCUTdiRXFWeTRfblFhNXNaOWlobXFkSGFMRVcwYjhxMVhJM01KenVRQll0QWpUcm…
Omada Health (OMDA) CFO sells 17,950 shares under Rule 10b5-1 plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNWkV4c2ZjYTNJbTItT3E4T21WN29WUlNrUU1LbnJuZ0taUUxaaVItUVBtTjZJbnpTMzdBcldzZ2lIcEcxNFFURXJ6a2dzak1qRmN6d0g3Tk9NTTk2NzVxMnRwWXFrR3F0b0N3dmw5YkowMkdnVmRXdTUwZ3o4WlhxT1ZkRnNPNWFQaUR3X0…
Omada Health CEO Sean P. Duffy sells $342,115 in company stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSXFLRW5kckVOOVdQSVZncHVWbHRIU0FhWFFnXzZhLWpMSkRPakVWWTQyalRKX3g4TTlBU0Y5XzhNT0VYdWlUUzNrVFlOYVEyLVcxY1ZwTTcyajJmSGhHZG95M1Fvb2NzSEhaMXJTaU9xNGRFRmZvUTlNTUhoT05iMVlOM3BGM3JjSVViWm…
OMDA — Frequently Asked Questions
What is the current share price of Omada Health, Inc. (OMDA)?
As of 2026-07-14 21:23 PDT, Omada Health, Inc. (OMDA) trades at $23.44 on NasdaqGS. Its 52-week range is $10.94 to $26.78.
What is the market capitalisation of OMDA?
Omada Health, Inc. (OMDA) has a market capitalisation of $1.39B on NasdaqGS.
What is the P/E ratio of OMDA?
OMDA trades at a trailing price-to-earnings (P/E) ratio of -101.91. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.34.
What is the return on equity (ROE) of OMDA?
OMDA has a return on equity (ROE) of -4.30%. Its return on capital employed (ROCE) is -5.21%.
Is OMDA a good stock to buy?
This page provides a data-driven analysis of Omada Health, Inc. (OMDA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.